Nintedanib could potentially lead to improvements in anti-melanoma differentiation-associated 5 dermatomyositis-associated interstitial lung disease

被引:1
作者
Chen, X. [1 ]
Jiang, W. [2 ]
Jin, Q. [1 ]
Lin, S. [3 ]
Zhang, L. [2 ]
Peng, Q. [2 ,5 ]
Sun, H. [4 ]
Wang, Y. [4 ]
Lu, X. [2 ,5 ]
Song, A. [6 ]
Wang, G. [1 ,2 ,5 ]
Ge, Y. [2 ,5 ]
机构
[1] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Rheumatol, 2 Yinghua Rd, Beijing 100029, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll, Beijing, Peoples R China
[4] China Japan Friendship Hosp, Dept Radiol, Beijing, Peoples R China
[5] China Japan Friendship Hosp, Dept Rheumatol, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China
[6] China Japan Friendship Hosp, Dept Pathol, Beijing, Peoples R China
关键词
dermatomyositis; nintedanib; anti-melanoma differentiation-associated protein 5 antibody; interstitial lung disease; CLASSIFICATION; PROGNOSIS; EFFICACY;
D O I
10.55563/clinexprheumatol/c0i032
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the efficacy and safety of nintedanib in patients with anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis-associated interstitial lung disease (anti-MDA5+ DM-ILD).<br /> Methods The study was a retrospective cohort design that evaluated patients with anti-MDA5+ DM who either received or did not receive nintedanib. Clinical symptoms, laboratory tests, and survival were compared in the two groups using a propensity score-matched analysis. The primary endpoint was mortality, while adverse events were recorded descriptively.<br /> Results After propensity score matching, 14 patients who received nintedanib (nintedanib+ group) and matched 56 patients who did not receive nintedanib (nintedanib- group) were enrolled. Compared with the nintedanib- group, the nintedanib+ group had a lower incidence of heliotrope and arthritis, higher lymphocyte counts, lower serum ferritin levels, and greater 12-month survival (all p<0.005). Although lung function, HRCT score, and lung VAS were not statistically different between the two groups, the longitudinal study showed significant improvement in HRCT scores (p=0.028) and pulmonary VAS (p=0.019) in the nintedanib+ group. Adverse events occurred in 28.6% of patients, with the most common adverse event with nintedanib being diarrhoea.<br /> Conclusion Nintedanib may be effective for improving clinical symptoms, laboratory parameters, lung lesions, and survival in anti-MDA5+ DM. Diarrhoea was the most common adverse event associated with nintedanib, although the drug was well tolerated by most patients.
引用
收藏
页码:386 / 393
页数:8
相关论文
共 50 条
[21]   Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis [J].
Hama, Satoshi ;
Akiyama, Mitsuhiro ;
Higashida-Konishi, Misako ;
Oshige, Tatsuhiro ;
Takei, Hiroshi ;
Izumi, Keisuke ;
Oshima, Hisaji ;
Okano, Yutaka .
MODERN RHEUMATOLOGY CASE REPORTS, 2023, 7 (01) :92-95
[22]   Rapidly progressive interstitial lung disease in patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis: serial changes on HRCT [J].
Minsoo Kim ;
Samuel Harvey ;
Sonye K. Danoff ;
Christopher A. Mecoli ;
Jemima Albayda ;
Julie J. Paik ;
Lisa Christopher-Stine ;
Peter B. Illei ;
Cheng Ting Lin .
Emergency Radiology, 2022, 29 :961-967
[23]   Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease [J].
Sun, Yuechi ;
He, Yan ;
Liu, Yuan ;
Shi, Guixiu .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2014, 15 (06) :521-524
[24]   The efficacy and safety of tofacitinib in anti-melanoma differentiation-associated gene 5 antibody positive dermatomyositis associated interstitial lung disease: a systematic review and meta-analysis [J].
Wang, Yanhong ;
Zou, Ruyi ;
Wei, Jie ;
Tang, Cheng ;
Wang, Junjie ;
Lin, Minjie .
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2024, 18
[25]   Blood purification in two patients with clinically amyopathic dermatomyositis associated with interstitial lung disease with anti-melanoma differentiation-associated gene-5 antibody (MDA-5) [J].
Shi, Han-yu ;
Li, Xue-ren ;
Wei, Lu-qing ;
Peng, Shou-chun .
RESPIRATORY MEDICINE CASE REPORTS, 2019, 28
[26]   Slowly progressive interstitial lung disease preceding typical dermatomyositis symptoms in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis [J].
Isono, Taisuke ;
Nakajima, Hiromi ;
Takano, Kenji ;
Kobayashi, Yoichi ;
Kawabata, Yoshinori ;
Shimizu, Yoshihiko ;
Takayanagi, Noboru .
RESPIRATORY MEDICINE CASE REPORTS, 2021, 34
[27]   Different clinical phenotypes in anti-melanoma differentiation-associated protein 5-associated positive dermatomyositis [J].
Pallo, P. A. Olivo ;
Shinjo, S. K. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) :394-394
[28]   Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease [J].
Lian, Xinyue ;
Ye, Yan ;
Zou, Jing ;
Wu, Chunmei ;
Ye, Shuang ;
Guo, Qiang ;
Chen, Sheng ;
Lu, Liangjing ;
Wang, Ran ;
Fu, Qiong ;
Bao, Chunde .
RHEUMATOLOGY, 2023, 62 (05) :1910-1919
[29]   Upfront combination therapy in anti-melanoma differentiation-associated gene 5 (MDA5) associated rapidly progressive interstitial lung disease [J].
Tseng, Chih-Wei .
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (06)
[30]   Mortality Risk Prediction in Patients With Antimelanoma Differentiation-Associated, Gene 5 Antibody-Positive, Dermatomyositis-Associated Interstitial Lung Disease: Algorithm Development and Validation [J].
Li, Hui ;
Zou, Ruyi ;
Xin, Hongxia ;
He, Ping ;
Xi, Bin ;
Tian, Yaqiong ;
Zhao, Qi ;
Yan, Xin ;
Qiu, Xiaohua ;
Gao, Yujuan ;
Liu, Yin ;
Cao, Min ;
Chen, Bi ;
Han, Qian ;
Chen, Juan ;
Wang, Guochun ;
Cai, Hourong .
JOURNAL OF MEDICAL INTERNET RESEARCH, 2025, 27